<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of cutaneous small vessel vasculitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of cutaneous small vessel vasculitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of cutaneous small vessel vasculitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carmen Gota, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter A Merkel, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The nomenclature of cutaneous small vessel vasculitis (CSVV) is diverse and often confusing. Names often used interchangeably but not always accurately, have included hypersensitivity angiitis, drug-induced vasculitis, leukocytoclastic vasculitis, cutaneous leukocytoclastic angiitis, serum sickness, serum sickness-like reactions, and allergic vasculitis. (See <a class="local">'Definitions'</a> below.)</p><p>This topic will present an overview of CSVV as a single-organ vasculitis limited to the skin. The evaluation and management of adults with cutaneous lesions of vasculitis are discussed in detail separately (see  <a class="medical medical_review" href="/d/html/13769.html" rel="external">"Evaluation of adults with cutaneous lesions of vasculitis"</a> and  <a class="medical medical_review" href="/d/html/13785.html" rel="external">"Management of adults with idiopathic cutaneous small vessel vasculitis"</a>). An overview of the approach to the vasculitides is also presented elsewhere. (See  <a class="medical medical_review" href="/d/html/8226.html" rel="external">"Overview of and approach to the vasculitides in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous small vessel vasculitis</strong> – Cutaneous small vessel vasculitis (CSVV) is defined as a single-organ, skin-isolated small vessel vasculitis or angiitis, often leukocytoclastic (LCV), without systemic vasculitis or glomerulonephritis [<a href="#rid1">1,2</a>].</p><p></p><p class="bulletIndent1">It is important to note that the same cutaneous presentation can be seen in many other systemic small vessel vasculitides such as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (eg, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, microscopic polyangiitis), cryoglobulinemic vasculitis, immunoglobulin A vasculitis (IgAV; Henoch-Schönlein purpura [HSP]), as well as other conditions such as infective endocarditis; thus, it should be regarded as a syndrome rather than a specific defined entity. When a patient presents with palpable purpura that reveals LCV on biopsy, the patient must be evaluated for a variety of causes and associated conditions (see  <a class="medical medical_review" href="/d/html/13769.html" rel="external">"Evaluation of adults with cutaneous lesions of vasculitis"</a> and  <a class="medical medical_review" href="/d/html/1825.html" rel="external">"Overview of cryoglobulins and cryoglobulinemia"</a>). Further delineation of etiology can only be done by integrating the clinical presentation, and in some cases (such as IgAV [HSP]), the presence or absence of vascular immunoglobulin deposition on skin biopsy. Some patients who are diagnosed initially as having a single organ cutaneous LCV can later develop a systemic form of small vessel vasculitis.</p><p></p><p class="bulletIndent1">Cutaneous polyarteritis nodosa is a medium vessel vasculitis, as discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/109628.html" rel="external">"Cutaneous polyarteritis nodosa"</a>.)</p><p></p><p>Other terms that have been used interchangeably with CSVV, but should be considered separately are defined below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukocytoclastic vasculitis</strong> – LCV is a histopathologic term that defines vasculitis of the small vessels in which the inflammatory infiltrate is composed of neutrophils. After degranulation, neutrophils undergo death and break down, a process named leukocytoclasia, releasing nuclear debris, also described as nuclear dust.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphocytic vasculitis</strong> – Lymphocytic vasculitis is not a universally accepted concept. The inflammatory infiltrate targeting the vessel wall (not merely trafficking through) is predominantly lymphocytic; the pathogenesis is presumed to be cell-mediated; it is not the result of a stage of evolution of LCV where neutrophils are replaced with mononuclear cells. It should also be differentiated from conditions associated with perivascular lymphocytic infiltrates without fibrinoid necrosis [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersensitivity vasculitis</strong> – Hypersensitivity vasculitis is a term originally used by Pearl Zeek in 1948 to differentiate small vessel necrotizing vasculitis attributed to a hypersensitivity reaction from the classic polyarteritis nodosa [<a href="#rid4">4</a>] (see  <a class="medical medical_review" href="/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults"</a>). Distinguishing features included prominent involvement of the skin, and the observation that the condition frequently appeared to be caused by a presumed "hypersensitivity" to serum or drugs. However, this term has fallen out of favor since the Chapel Hill 1994 consensus on the classification of vasculitides excluded the term because of a lack of specificity of clinical (palpable purpura) and histologic presentation (LCV), as well as the inability to describe the precise immune mechanism that caused the small vessel vasculitis. Patients who previously would have been classified as having hypersensitivity vasculitis are now diagnosed with cutaneous small vessel vasculitis if vasculitis is limited to the skin, or with another type of specific small vessel vasculitis if there is evidence of systemic involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum sickness</strong> – Serum sickness and serum sickness-like reaction are terms that are often used inconsistently. Historically, they have been applied to a clinical pathologic syndrome occurring 8 to 12 days after exposure to a therapeutic administration of foreign proteins. Consensus opinion would apply the diagnostic term "serum sickness" to the development of a rash (generally urticarial, morbilliform, or even angioedema), arthralgia, arthritis, and fever occurring 5 to 14 days after foreign protein, protein-based therapeutic biologic, or other drug exposure. Serum sickness and serum sickness-like reactions are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2078.html" rel="external">"Serum sickness and serum sickness-like reactions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune complex small vessel vasculitis</strong> – Immune complex small vessel vasculitis refers to vasculitis associated with immune complex and/or complement deposition, predominantly affecting small vessels. If limited to the skin, this is identical to cutaneous small vessel vasculitis. However, other systemic manifestations may occur, such as glomerulonephritis. When appropriate, immune complex vasculitis can be characterized as vasculitis associated with probable etiologies such as cryoglobulinemic vasculitis related to hepatitis C, systemic lupus erythematosus (SLE), Sjögren's disease, or rheumatoid arthritis [<a href="#rid1">1</a>]. Other examples of immune complex small vessel vasculitis include antiglomerular basement membrane disease, IgAV (HSP), and hypocomplementemic urticarial vasculitis. (See  <a class="medical medical_review" href="/d/html/8226.html" rel="external">"Overview of and approach to the vasculitides in adults", section on 'Immune complex small-vessel vasculitis'</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h1">ETIOPATHOGENESIS</span><span class="headingEndMark"> — </span>Almost all classes of drugs have been associated with cutaneous small vessel vasculitis (CSVV), but penicillins, cephalosporins, sulfonamides (including most loop and thiazide-type diuretics), <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, and <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a> have been most often implicated  (<a class="graphic graphic_table graphicRef81148" href="/d/graphic/81148.html" rel="external">table 1</a>) [<a href="#rid5">5,6</a>]. Drugs may act as haptens to stimulate an immune response. Certain infections, such as hepatitis due to hepatitis B or C virus, chronic bacteriemias (eg, infective endocarditis, infected shunts), and human immunodeficiency virus (HIV), and other viruses, may also be associated with CSVV [<a href="#rid6">6-8</a>]. CSVV has been reported with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and vaccinations [<a href="#rid9">9,10</a>].</p><p>CSVV is often mediated by immune complex deposition in the small vessels. Evidence for circulating immune complex formation includes the detection of soluble complexes, hypocomplementemia in many patients (but not immunoglobulin A vasculitis [IgAV; Henoch-Schönlein purpura (HSP)]), and the deposition of immune reactants in vessels [<a href="#rid11">11,12</a>].</p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The major clinical findings include palpable purpura (0.3 to 1 cm diameter) and/or petechiae (purpuric lesions less than 3 mm in diameter) that are nonblanching  (<a class="graphic graphic_picture graphicRef94489" href="/d/graphic/94489.html" rel="external">picture 1</a>). Sometimes these lesions coalesce, ulcerate, or are surrounded by hemorrhagic bullae. Urticarial lesions, which have a histologic pattern consistent with leukocytoclastic vasculitis, can also be observed. When the inciting agent is a drug or infectious agent, most patients develop symptoms and/or findings beginning 7 to 10 days after antigen exposure, which is the time required to produce a sufficient quantity of antibody to produce antigen-antibody complexes [<a href="#rid13">13</a>]. However, the latent period may be as short as two to seven days with a secondary antigen exposure, or may be longer than two weeks with a long-acting drug such as benzathine G penicillin [<a href="#rid14">14</a>].</p><p>By definition, in cutaneous small vessel vasculitis (CSVV) there is no visceral organ involvement. However, visceral involvement can occur later in the disease course, revealing a systemic small vessel vasculitic process. </p><p>In cases of immune complex-mediated vasculitis when the inciting agent persists, such as in hepatitis C-related cryoglobulinemic vasculitis, lupus erythematosus, or rheumatoid arthritis, chronic vasculitis can be observed, with waxing and waning lesions or persistent lesions of different ages. (See  <a class="medical medical_review" href="/d/html/3676.html" rel="external">"Extrahepatic manifestations of hepatitis C virus infection"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of cutaneous small vessel vasculitis (CSVV) is usually suggested by the clinical findings and by the history of an offending drug or infection [<a href="#rid15">15</a>]. If immunoglobulins such as immunoglobulin G (IgG), IgM and/or complement deposition are found on immunofluorescence, an immune complex mechanism is suggested as a cause. The absence of immune complex deposition may be due to late timing of biopsy relative to onset of skin lesion, or may be associated in some cases (but not always) with a pauciimmune type of vasculitis such as microscopic polyangiitis. If IgA deposition is noted on immunofluorescence microscopy of the skin lesion biopsy, and there is a history of joint or gastrointestinal symptoms, an assessment of urine sediment should take place and be repeated on subsequent visits. Immunoglobulin A vasculitis (IgAV), formerly known as Henoch-Schönlein purpura (HSP) is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H369682248"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>The evaluation of the patient with cutaneous lesions suspicious for vasculitis is directed at addressing these questions:</p><p class="bulletIndent1"><span class="glyph">●</span>Is this vasculitis?</p><p class="bulletIndent1"><span class="glyph">●</span>Are other organs involved?</p><p class="bulletIndent1"><span class="glyph">●</span>What is the cause?</p><p></p><p>A history of new drugs and associated comorbidities (eg, infections, hepatitis C, or a systemic rheumatic disease) should be ascertained.</p><p>A comprehensive history and detailed physical examination should also be performed to determine whether the process is truly skin-limited, and that no organ-threatening systemic disease coexists. While the patient may only complain of the rash, more ominous damage, potentially irreversible and/or life-threatening, can coexist in other organs, such as alveolar hemorrhage, glomerulonephritis, mesenteric ischemia, or mononeuritis multiplex. Particular attention must be paid to potential organs targeted in small vessel vasculitis such as, but not limited to: lungs, kidneys, gastrointestinal tract, and peripheral and central nervous system.</p><p class="headingAnchor" id="H369682045"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>The possibility of an underlying systemic disease must always be considered in a patient presenting with lesions suspicious for cutaneous vasculitis  (<a class="graphic graphic_table graphicRef59048" href="/d/graphic/59048.html" rel="external">table 2</a>). Suggested laboratory tests are discussed separately (See  <a class="medical medical_review" href="/d/html/13769.html" rel="external">"Evaluation of adults with cutaneous lesions of vasculitis", section on 'Evaluation for etiology and extracutaneous involvement'</a>.)</p><p class="headingAnchor" id="H369682051"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>Cutaneous lesions suspicious for vasculitis should be biopsied in almost all adult patients. Some experts feel that not all children need to have a biopsy performed. The pattern of cutaneous pathology and immunology is highly sensitive to the timing of the biopsy and the age of the lesion, with the lesions between 24 to 48 hours old preferred for biopsy. The core histological features on biopsy are infiltration with polymorphonuclear neutrophils in and around the vessel walls, with signs of activation, degranulation, and death of neutrophils illustrated by leukocytoclasia (nuclear dust); evidence of tissue damage (extravasated red blood cells, damaged endothelial cells, and occasionally necrosis of skin appendages); and fibrinoid necrosis  (<a class="graphic graphic_picture graphicRef94489" href="/d/graphic/94489.html" rel="external">picture 1</a>). A biopsy sample should also be sent for direct immunofluorescence (DIF) studies, but this specimen should be taken from the newest lesion that is able to be identified. A detailed discussion of the biopsy of patients with cutaneous vasculitis is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/13769.html" rel="external">"Evaluation of adults with cutaneous lesions of vasculitis", section on 'Skin biopsy to confirm vasculitis'</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Cutaneous small vessel vasculitis (CSVV) may be impossible to distinguish from other forms of systemic vasculitis, unless other manifestations are present. In addition, palpable purpura and petechial lesions can also be present in other conditions. Examples of conditions that may present with cutaneous lesions of vasculitis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic vasculitides such as microscopic polyarteritis, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), immunoglobulin A vasculitis (IgAV; Henoch-Schönlein purpura [HSP]), other systemic immune complex vasculitides, and polyarteritis nodosa (including that due to hepatitis B), may present with predominantly cutaneous involvement, such as palpable purpura  (<a class="graphic graphic_table graphicRef59048" href="/d/graphic/59048.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Palpable purpura may, at times, be the presentation of paraneoplastic or malignancy-associated forms of vasculitis frequently due to a lymphoproliferative disease. These patients tend to have chronic purpura, often treatment resistant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The same process of red cell extravasation associated with purpuric skin lesions seen in vasculitis can be caused by noninflammatory vascular damage such as in scurvy, Ehlers-Danlos syndrome, cholesterol emboli, actinic and senile purpura, or glucocorticoid-induced purpura; or by coagulation and platelet disorders such as autoimmune thrombocytopenia or thrombotic thrombocytopenic purpura.</p><p></p><p>A more comprehensive list of differential diagnoses can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/13769.html" rel="external">"Evaluation of adults with cutaneous lesions of vasculitis", section on 'Types of cutaneous vasculitis'</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Once systemic involvement has been excluded and the diagnosis of single-organ cutaneous small vessel vasculitis (CSVV) has been made, the treatment is largely focused on symptom management. For cases in which the cause is thought to be due to a drug, discontinuation of the inciting drug or antigen should lead to resolution within a period of days to a few weeks. The recognition of CSVV due to an ongoing infection is also important since the administration of immunosuppressive medications may be harmful. In such cases, treatment should be aimed at the underlying infection, such as the administration of antibiotics for patients with endocarditis or antivirals for patients with hepatitis C or HIV.</p><p>Occasionally, patients develop persistent symptoms that may require systemic immunomodulatory drugs. For cases in which the cutaneous vasculitis is refractory to immunosuppressive therapy, a sustained search for an underlying cause, including malignancy, is indicated [<a href="#rid16">16</a>]. A discussion of the management of adults with cutaneous small vessel vasculitis is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/13785.html" rel="external">"Management of adults with idiopathic cutaneous small vessel vasculitis", section on 'Management'</a>.)</p><p class="headingAnchor" id="H3323908158"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110743.html" rel="external">"Society guideline links: Vasculitis"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/579.html" rel="external">"Patient education: Vasculitis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H86082342"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Cutaneous small vessel vasculitis (CSVV) is defined as a single-organ, skin-isolated leukocytoclastic vasculitis (LCV) or angiitis without systemic vasculitis or glomerulonephritis. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiopathogenesis</strong> – Many medications that can cause cutaneous vasculitis include penicillins, cephalosporins, sulfonamides (including most loop and thiazide-type diuretics), <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, and <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a>  (<a class="graphic graphic_table graphicRef81148" href="/d/graphic/81148.html" rel="external">table 1</a>). Certain infections, such as hepatitis due to hepatitis B or C virus, chronic bacteriemias (eg, infective endocarditis, infected shunts), and HIV, and other viruses, may also be associated with CSVV. (See <a class="local">'Etiopathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The major clinical findings, include palpable purpura (0.3 to 1 cm diameter), and/or petechiae (purpuric lesions less than 3 mm in diameter), that are nonblanching  (<a class="graphic graphic_picture graphicRef94489" href="/d/graphic/94489.html" rel="external">picture 1</a>). (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of CSVV is usually suggested by the clinical findings and by the history of an offending drug or infection. A comprehensive history and detailed physical examination must be performed to determine whether the process is truly skin-limited, and that no organ-threatening systemic vasculitis or other disease coexists  (<a class="graphic graphic_table graphicRef59048" href="/d/graphic/59048.html" rel="external">table 2</a>). Cutaneous lesions suspicious for vasculitis must be biopsied. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis for CSVV is broad and includes systemic vasculitides  (<a class="graphic graphic_table graphicRef59048" href="/d/graphic/59048.html" rel="external">table 2</a>), paraneoplastic or malignancy-associated vasculitis, and a variety of other causes of noninflammatory vascular damage such as scurvy, Ehlers-Danlos syndrome, cholesterol emboli, actinic and senile purpura, or glucocorticoid-induced purpura; or coagulation and platelet disorders such as autoimmune thrombocytopenia or thrombotic thrombocytopenic purpura. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Once systemic involvement has been excluded and the diagnosis of single-organ CSVV has been made, the treatment is largely focused on symptom management. (See <a class="local">'Treatment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.</a></li><li><a class="nounderline abstract_t">Sunderkötter CH, Zelger B, Chen KR, et al. Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatol 2018; 70:171.</a></li><li><a class="nounderline abstract_t">Kossard S. Defining lymphocytic vasculitis. Australas J Dermatol 2000; 41:149.</a></li><li><a class="nounderline abstract_t">ZEEK PM. Periarteritis nodosa and other forms of necrotizing angiitis. N Engl J Med 1953; 248:764.</a></li><li><a class="nounderline abstract_t">Mullick FG, McAllister HA Jr, Wagner BM, Fenoglio JJ Jr. Drug related vasculitis. Clinicopathologic correlations in 30 patients. Hum Pathol 1979; 10:313.</a></li><li><a class="nounderline abstract_t">Martinez-Taboada VM, Blanco R, Garcia-Fuentes M, Rodriguez-Valverde V. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med 1997; 102:186.</a></li><li><a class="nounderline abstract_t">Sais G, Vidaller A, Jucglà A, et al. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol 1995; 131:1399.</a></li><li><a class="nounderline abstract_t">Blanco R, Martínez-Taboada VM, Rodríguez-Valverde V, García-Fuentes M. Cutaneous vasculitis in children and adults. Associated diseases and etiologic factors in 303 patients. Medicine (Baltimore) 1998; 77:403.</a></li><li><a class="nounderline abstract_t">McGonagle D, Bridgewood C, Ramanan AV, et al. COVID-19 vasculitis and novel vasculitis mimics. Lancet Rheumatol 2021; 3:e224.</a></li><li><a class="nounderline abstract_t">Corrà A, Verdelli A, Mariotti EB, et al. Cutaneous vasculitis: Lessons from COVID-19 and COVID-19 vaccination. Front Med (Lausanne) 2022; 9:1013846.</a></li><li><a class="nounderline abstract_t">Tosca N, Stratigos JD. Possible pathogenetic mechanisms in allergic cutaneous vasculitis. Int J Dermatol 1988; 27:291.</a></li><li><a class="nounderline abstract_t">van Rossum AP, Pas HH, Fazzini F, et al. Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis. Arthritis Rheum 2006; 54:986.</a></li><li><a class="nounderline abstract_t">Leavitt RY, Fauci AS. Polyangiitis overlap syndrome. Classification and prospective clinical experience. Am J Med 1986; 81:79.</a></li><li><a class="nounderline abstract_t">Parker CW. Allergic reactions in man. Pharmacol Rev 1982; 34:85.</a></li><li><a class="nounderline abstract_t">Loricera J, Blanco R, Ortiz-Sanjuán F, et al. Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases. Rheumatology (Oxford) 2015; 54:77.</a></li><li><a class="nounderline abstract_t">Micheletti RG, Pagnoux C. Management of cutaneous vasculitis. Presse Med 2020; 49:104033.</a></li></ol></div><div id="topicVersionRevision">Topic 8241 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23045170" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29136340" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10954985" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Defining lymphocytic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13046612" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Periarteritis nodosa and other forms of necrotizing angiitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/468217" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Drug related vasculitis. Clinicopathologic correlations in 30 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217569" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical features and outcome of 95 patients with hypersensitivity vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7492128" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854604" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cutaneous vasculitis in children and adults. Associated diseases and etiologic factors in 303 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33521655" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : COVID-19 vasculitis and novel vasculitis mimics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36569148" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cutaneous vasculitis: Lessons from COVID-19 and COVID-19 vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3292447" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Possible pathogenetic mechanisms in allergic cutaneous vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16508993" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2873744" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Polyangiitis overlap syndrome. Classification and prospective clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7041144" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Allergic reactions in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25065012" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32645416" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Management of cutaneous vasculitis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
